Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that FLT3-ITD status confers therapeutic sensitivity to Gilteritinib in patients with Acute Myeloid Leukemia.
The Republic of Ireland's Health Service Executive (HSE) has approved gilteritinib as a treatment option for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation. In the event that patients re-initiate gilteritinib post haematopoietic stem cell transplant (HSCT) as maintenance therapy, gilteritinib treatment should be restricted to patients who are minimal residual disease (MRD)-positive post-transplant.
This statement is based on a regulatory approval from the Health Service Executive:
As monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation. In the event that patients re-initiate gilteritinib post haematopoietic stem cell transplant (HSCT) as maintenance therapy, gilteritinib treatment should be restricted to patients who are minimal residual disease (MRD)-positive post-transplant.
Citation
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2025-10-01 | Health Service Executive | Indication approved for reimbursement. |
| 2024-01-16 | Van Allen lab | Adding HSE approvals for reimbursement to database |